2026年欧洲肿瘤内科学会乳腺癌年会（ESMO BC）将于当地时间5月6日至8日在德国柏林举行。本次大会内容丰富、亮点纷呈，全面覆盖乳腺癌的靶向治疗、内分泌治疗以及免疫治疗等领域，届时将有多项极具影响力的研究成果公布。《肿瘤瞭望-乳腺时讯》特别对会议即将披露的重要研究内容进行了系统汇总，以飨读者。
编者按：2026年欧洲肿瘤内科学会乳腺癌年会（ESMO BC）将于当地时间5月6日至8日在德国柏林举行。本次大会内容丰富、亮点纷呈，全面覆盖乳腺癌的靶向治疗、内分泌治疗以及免疫治疗等领域，届时将有多项极具影响力的研究成果公布。《肿瘤瞭望-乳腺时讯》特别对会议即将披露的重要研究内容进行了系统汇总，以飨读者。
Proffered Paper session 1
时间：5月6日16:00-17:30
地点：Berlin Hall
主席：Sara M.Tolaney(Boston，MA，United States of America)Masakazu Toi(Bunkyo-ku，Japan)
LBA1-Residual cancer burden(RCB)following neoadjuvant treatment(NAT)with trastuzumab deruxtecan(T-DXd)followed by paclitaxel+trastuzumab+pertuzumab(THP)vs dose-dense doxorubicin+cyclophosphamide followed by THP(ddAC-THP)in high-risk HER2+early-stage breast cancer(eBC)
高危HER2+早期乳腺癌（eBC）新辅助治疗（NAT）后T-DXd序贯紫杉醇+曲妥珠单抗+帕妥珠单抗（THP）与剂量密集多柔比星+环磷酰胺序贯THP（ddAC-THP）的残余肿瘤负荷（RCB）比较
报告时间：16:00-16:10
讲者：Lajos Pusztai(New Haven，CT，United States of America)
214O-Chemotherapy-free，pathological complete response(pCR)-guided strategy with trastuzumab-pertuzumab(HP)and T-DM1 in HER2+early breast cancer(EBC):PHERGain-2
曲妥珠单抗-帕妥珠单抗（HP）和T-DM1治疗HER2+早期乳腺癌（EBC）的无化疗、病理完全缓解（pCR）指导策略：PHERGain-2
报告时间：16:10-16:20
讲者：Antonio LLOMBART CUSSAC(Valencia，Spain)
215O-Randomized，phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine for triple-negative breast cancer(TNBC)with residual invasive cancer after neoadjuvant chemotherapy(MIRINAE trial，KCSG-BR18-21)
一项随机II期试验，旨在评估阿替利珠单抗联合卡培他滨辅助治疗对比卡培他滨单药治疗新辅助化疗后残留浸润性癌的三阴性乳腺癌(TNBC)的疗效和安全性（MIRINAE试验，KCSG-BR18-21）
报告时间：16:20-16:30
讲者：In Hae Park(Seoul，Republic of Korea)
1O-ctDNA detection rates during surveillance in high-risk HR+/HER2 negative breast cancer from the TRAK-ER study
TRAK-ER研究中高危HR+/HER2阴性乳腺癌监测期间ctDNA的检出率
报告时间：16:52-17:02
讲者：Niamh Cunningham(London，United Kingdom)
LBA2-A window-of-opportunity(WOO)trial of giredestrant+/-LHRH analogue vs anastrozole+LHRHa in premenopausal patients with ER+/HER2-early breast cancer:PREcoopERA
一项在ER+/HER2-早期乳腺癌绝经前患者中评估giredestrant±LHRH类似物对比阿那曲唑+LHRH类似物的机会窗（WOO）试验：PREcoopERA
报告时间：17:02-17:12
讲者：Elisabetta Munzone(Milan，Italy)
Rapid Oral session 1
时间：5月7日08:30-10:00
地点：Berlin Hall
主席：Sonia Pernas(Hospitalet de Llobregat，Spain)Peter Dubsky(Luzern，Switzerland)
216RO-5-year invasive disease-free survival(iDFS)of the strategy-based，randomized phase II PHERGain trial evaluating chemotherapy(CT)de-escalation in HER2[+]early breast cancer(EBC)patients(pts)
基于策略的随机Ⅱ期PHERGain试验评估HER2+早期乳腺癌（EBC）患者化疗（CT）降阶治疗的5年无侵袭性疾病生存期（iDFS）
报告时间：08:30-08:35
讲者：Javier C.Cortés(Barcelona，Spain)
217RO-Neoadjuvant trastuzumab，pertuzumab and tucatinib without chemotherapy in HER2+early breast cancer:The TRAIN-4 study
新辅助曲妥珠单抗、帕妥珠单抗联合图卡替尼治疗HER2阳性早期乳腺癌，无需化疗：TRAIN-4研究
报告时间：08:35-08:40
讲者：Fleur M.Louis(Amsterdam，Netherlands)
2RO-Tumor-informed ctDNA dynamics and efficacy of sequential pyrotinib–pertuzumab neoadjuvant therapy in HER2-positive breast cancer:A randomized，open-label，phase II trial
肿瘤相关ctDNA动态变化及序贯吡咯替尼-帕妥珠单抗新辅助治疗在HER2阳性乳腺癌中的疗效：一项随机、开放标签的II期试验
报告时间：08:40-08:45
讲者：Haoyu Wang(上海交通大学医学院附属瑞金医院)
3RO-Improved identification of high-risk node-negative breast cancer using a multimodal clinical，pathologic，and genomic model in the TAILORx Trial
在TAILORx试验中，利用多模态临床、病理和基因组模型改进了高危淋巴结阴性乳腺癌的识别
报告时间：09:00-09:05
讲者：Frederick M.Howard(Chicago，IL，United States of America)
218RO-Revisiting estrogen receptor positivity in breast cancer:Long-term outcomes and endocrine therapy benefit across ER expression levels
重新审视乳腺癌中雌激素受体阳性亚型：不同雌激素受体表达水平下的长期预后和内分泌治疗获益
报告时间：09:05-09:10
讲者：Flora Nguyen Van Long(Quebec，QC，Canada)
187RO-Lymph node surgery and CDK4/6 inhibitors in early breast cancer:A cost-consequence analysis from 5 randomized trials
早期乳腺癌淋巴结手术和CDK4/6抑制剂：来自5项随机试验的成本效益分析
报告时间：09:10-09:15
讲者：Andre Pfob(Heidelberg，Germany)
4RO-A comparative analysis between tissue-free ctDNA detection and a multivariant tumour-informed assay in early triple-negative breast cancer
早期三阴性乳腺癌中无组织ctDNA检测与多变量肿瘤信息检测的比较分析
报告时间：09:15-09:20
讲者：Niamh Cunningham(London，United Kingdom)
LBA3-The UK retrospective genetic testing programme:Utilising linkage of nationally collected data to identify and offer germline genetic testing to patients with historic diagnoses of breast or ovarian cancer
英国回顾性基因检测计划：利用国家收集的数据的链接来确定和提供生殖细胞系基因检测给有乳腺癌或卵巢癌病史的患者
报告时间：09:44-09:49
讲者：Clare A.Turnbull(London，United Kingdom)
LBA5-Efficacy of an mHealth intervention to address informational needs in adolescent and young adult(AYA)breast cancer survivors(BCS):A secondary outcome from the YES trial
移动医疗干预对满足青少年和年轻成人（AYA）乳腺癌幸存者（BCS）信息需求的效果：YES试验的次要结局
报告时间：09:54-09:59
讲者：Shoshana M.Rosenberg(New York，NY，United States of America)
Proffered Paper session 2
时间：5月7日14:15-15:45
地点：Berlin Hall
主席：Nicholas C.Turner(London，United Kingdom)
418O-Safety and patient(pt)-reported outcomes(PROs)from evERA breast cancer(BC):A phase III trial of giredestrant(GIRE)+everolimus(E)in pts with oestrogen receptor-positive，HER2-negative advanced BC(ER+，HER2–aBC)previously treated with a CDK4/6 inhibitor(i)
evERA BC研究的安全性和患者报告结局（PRO）：一项III期试验，评估giredestrant+依维莫司在既往接受过CDK4/6抑制剂治疗的雌激素受体阳性、HER2阴性晚期乳腺癌（ER+，HER2–aBC）)患者中的疗效
报告时间：14:15-14:25
讲者：Miguel Martin(Madrid，Spain)
415O-First-line(1L)datopotamab deruxtecan(Dato-DXd)vs chemotherapy(CT)in patients(pts)with locally recurrent inoperable or metastatic triple-negative breast cancer(mTNBC)for whom immunotherapy was not an option:Patient-reported outcomes(PROs)from TROPION-Breast02
在不能接受免疫治疗的局部复发、不可手术或转移性三阴性乳腺癌（mTNBC）患者（pts）中，一线（1L）datopotamab deruxtecan（Dato-DXd）与化疗（CT）的比较：TROPION-Breast02研究的患者报告结局（PRO）
报告时间：14:25-14:35
讲者：Peter Schmid(London，United Kingdom)
416O-SMART:On-treatment ctDNA dynamics predicts response and progression in metastatic breast cancer
SMART：治疗期间ctDNA动态变化可预测转移性乳腺癌的疗效和进展
报告时间：14:53-15:03
讲者：Pedram Razavi(New York，NY，United States of America)
417O-Capivasertib(C)and fulvestrant(F)for patients(pts)with HR+/HER2−advanced breast cancer(ABC):Final overall survival(OS)results from the phase III CAPItello-291 trial
卡匹色替联合氟维司群用于HR+/HER2-晚期乳腺癌（ABC）患者：III期CAPItello-291试验的最终总生存期（OS）结果
报告时间：15:03-15:13
讲者：Hope S.Rugo(Los Angeles，CA，United States of America)
Rapid Oral session 2
时间：5月8日08:30-10:00
地点：Berlin Hall
419RO-Emergence of ESR1 mutations(ESR1m)in ctDNA during first-line(1L)endocrine-based therapy in HR+/HER2-advanced breast cancer:Findings from the SERENA-6 trial
在HR+/HER2-晚期乳腺癌一线内分泌治疗期间，ctDNA中ESR1突变（ESR1m）的出现情况：SERENA-6试验的结果
报告时间：08:30-08:35
讲者：François Clément Bidard(Paris，France)
420RO-Efficacy of inavolisib(INAVO)+palbociclib(PALBO)+fulvestrant(FULV)in patients(pts)with PIK3CA-mutated，hormone receptor-positive，HER2-negative(HER2–)，endocrine-resistant advanced breast cancer(aBC)with and without hyperglycaemia(HG)in the phase III INAVO120 trial
在III期INAVO120试验中，评估伊利那塞+哌柏西利+氟维司群联合治疗PIK3CA突变、激素受体阳性、HER2阴性、内分泌耐药的晚期乳腺癌（aBC）患者（伴或不伴高血糖）的疗效
报告时间：08:35-08:40
讲者：Sibylle Loibl(Neu-Isenburg，Germany)
421RO-Dose optimization of BTX-9341，a first-in-class CDK4/6 bifunctional degrader，in CDK4/6 inhibitor-pretreated HR+/HER2−advanced/metastatic breast cancer
在接受过CDK4/6抑制剂治疗的HR+/HER2-晚期/转移性乳腺癌患者中，BTX-9341（一种首创的CDK4/6双功能降解剂）的剂量优化
报告时间：08:40-08:45
讲者：Matthew P.Goetz(Rochester，NY，United States of America)
422RO-A phase II study of patritumab deruxtecan(HER3-DXd)in patients(pts)with metastatic breast cancer(MBC)
Patritumab Deruxtecan（HER3-DXd）治疗转移性乳腺癌（MBC）患者的II期研究
报告时间：09:00-09:05
讲者：Erika P.Hamilton(Nashville，TN，United States of America)
LBA4-Efficacy and safety of sacituzumab govitecan(SG)plus trastuzumab in patients with HER2+metastatic breast cancer after prior trastuzumab deruxtecan(T-DXd):Results from the phase II SATEEN trial
sacituzumab govitecan（SG）联合曲妥珠单抗治疗既往接受过T-DXd治疗的HER2+转移性乳腺癌患者的疗效和安全性：2期SATEEN试验的结果
报告时间：09:10-09:15
讲者：Paolo Tarantino(Boston，MA，United States of America)
423RO-Addition of tucatinib to trastuzumab emtansine(T-DM1)in patients with previously treated HER2+locally advanced/metastatic breast cancer(LA/MBC):Updated efficacy analysis from the HER2CLIMB-02 trial
在既往接受过治疗的HER2阳性局部晚期/转移性乳腺癌(LA/MBC)患者中，T-DM1联合图卡替尼治疗方案的疗效：HER2CLIMB-02试验的最新疗效分析
报告时间：09:15-09:20
讲者：Giuseppe Curigliano(Milan，Italy)
424RO-SACI-IO HR+:Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative(HR+/HER2-)metastatic breast cancer(MBC)
SACI-IO HR+：一项随机II期试验的最终结果，该试验评估了戈沙妥珠单抗联合或不联合帕博利珠单抗治疗激素受体阳性/HER2阴性(HR+/HER2-)转移性乳腺癌(MBC)的疗效
报告时间：09:35-09:40
讲者：Ana C.Garrido-Castro(Boston，MA，United States of America)
425RO-A randomized phase II study of pembrolizumab plus carboplatin vs.carboplatin alone in unresectable advanced breast cancer(ABC)with chest wall disease(CWD)[ICI-CHEST，TBCRC 44]
一项随机II期研究比较了帕博利珠单抗联合卡铂与单用卡铂治疗不可切除的晚期乳腺癌（ABC）伴胸壁疾病（CWD）的疗效[ICI-CHEST，TBCRC 44]
报告时间：09:40-09:45
讲者：Neelima Vidula(Boston，MA，United States of America)
426RO-Pumitamig in combination with DB-1305/BNT325 as first-line(1L)treatment for patients with advanced or metastatic triple-negative breast cancer(a/mTNBC):Efficacy and safety from a multicenter，open-label，phase I/II trial
Pumitamig联合DB-1305/BNT325作为一线（1L）治疗晚期或转移性三阴性乳腺癌（a/mTNBC）患者的疗效和安全性：一项多中心、开放标签的1/2期试验
报告时间：09:45-09:50
讲者：张剑（复旦大学附属肿瘤医院）
京公网安备 11010502033352号